Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revisionBoth sides next revision | ||
content:neonatal_seizures [2020/02/23 14:35] – [Management] icna | content:neonatal_seizures [2020/02/23 14:42] – [Management] icna | ||
---|---|---|---|
Line 186: | Line 186: | ||
* FDA-approved for children as young as one-month of age[(: | * FDA-approved for children as young as one-month of age[(: | ||
* efficacy and safety profile has not been adequately studied in term or preterm neonates within the first month of life | * efficacy and safety profile has not been adequately studied in term or preterm neonates within the first month of life | ||
- | * dosing of 40–50mg/ | + | |
+ | | ||
* a recent open labelled RCT (Level III neonatal unit; 100 neonates) used Levetiracetam (20 mg/kg) or Phenobarbitone (20 mg/kg) intravenously and concluded that Levetiracetam achieves better control than Phenobarbitone for neonatal clinical seizures when used as first-line antiepileptic drug, and is not associated with adverse drug reactions[(: | * a recent open labelled RCT (Level III neonatal unit; 100 neonates) used Levetiracetam (20 mg/kg) or Phenobarbitone (20 mg/kg) intravenously and concluded that Levetiracetam achieves better control than Phenobarbitone for neonatal clinical seizures when used as first-line antiepileptic drug, and is not associated with adverse drug reactions[(: | ||
* phenytoin/ | * phenytoin/ | ||
Line 204: | Line 205: | ||
* consider pyridoxine challenge when other antiepileptics provide no response | * consider pyridoxine challenge when other antiepileptics provide no response | ||
* minimal data for many antiepileptics including topiramate, which is being increasingly used in neonates | * minimal data for many antiepileptics including topiramate, which is being increasingly used in neonates | ||
- | * steroids and / or vigabatrin are considered in epileptic spasms | + | * steroids and / or [[vigabatrin]] are considered in epileptic spasms |
- | * tonic seizures related to benign familial neonatal | + | * Low-dose carbamazepine (CBZ) should be considered as first-line treatment for benign familial neonatal |
* there is equipoise on levetiracetam vs phenobarbitone as first line treatment[(: | * there is equipoise on levetiracetam vs phenobarbitone as first line treatment[(: | ||
- | * The 2011 World Health Organization (WHO) guidelines for neonatal seizures[(: | + | * The 2011 World Health Organization (WHO) guidelines for neonatal seizures[(: |